Evaluating the role of zinc in the occurrence of fibrosis of the skin: A preclinical study

To investigate the possible role of Zn as a trigger for NSF we were using a previously established preclinical model. The depletion of endogenous Zinc ions (Zn) caused by the administration of gadolinium‐based contrast agents (GBCAs) has been suggested as a possible pathomechanism for nephrogenic systemic fibrosis (NSF).

[1]  T. Steger-Hartmann,et al.  Impact of Renal Impairment on Long-Term Retention of Gadolinium in the Rodent Skin Following the Administration of Gadolinium-Based Contrast Agents , 2009, Investigative radiology.

[2]  T. Frenzel,et al.  Long-term retention of gadolinium in the skin of rodents following the administration of gadolinium-based contrast agents , 2009, European Radiology.

[3]  T. Frenzel,et al.  Stability of Gadolinium-Based Magnetic Resonance Imaging Contrast Agents in Human Serum at 37°C , 2008, Investigative radiology.

[4]  Martin R Prince,et al.  Incidence of nephrogenic systemic fibrosis at two large medical centers. , 2008, Radiology.

[5]  Diego R Martin,et al.  Risk of nephrogenic systemic fibrosis: evaluation of gadolinium chelate contrast agents at four American universities. , 2008, Radiology.

[6]  T. Frenzel,et al.  Preclinical investigation to compare different gadolinium-based contrast agents regarding their propensity to release gadolinium in vivo and to trigger nephrogenic systemic fibrosis-like lesions , 2008, European Radiology.

[7]  Hanns-Joachim Weinmann,et al.  Gadolinium‐based contrast agents and their potential role in the pathogenesis of nephrogenic systemic fibrosis: The role of excess ligand , 2008, Journal of magnetic resonance imaging : JMRI.

[8]  H. Hussain,et al.  Nephrogenic systemic fibrosis: a report of 29 cases. , 2008, AJR. American journal of roentgenology.

[9]  T. Frenzel,et al.  A Preclinical Study to Investigate the Development of Nephrogenic Systemic Fibrosis: A Possible Role for Gadolinium-Based Contrast Media , 2008, Investigative radiology.

[10]  D. Tudorascu,et al.  Nephrogenic systemic fibrosis: Center case review , 2007, Journal of magnetic resonance imaging : JMRI.

[11]  H. Schmitt-Willich.  Stability of linear and macrocyclic gadolinium based contrast agents. , 2007, The British journal of radiology.

[12]  S. Cowper,et al.  Nephrogenic systemic fibrosis: a population study examining the relationship of disease development to gadolinium exposure. , 2007, Clinical journal of the American Society of Nephrology : CJASN.

[13]  J. Finsterer,et al.  Dermal and extra-dermal manifestations of gadolinium-triggered nephrogenic fibrosing dermopathy. , 2006, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[14]  Lone Skov,et al.  Nephrogenic systemic fibrosis: suspected causative role of gadodiamide used for contrast-enhanced magnetic resonance imaging. , 2006, Journal of the American Society of Nephrology : JASN.

[15]  T. Grobner.  Gadolinium--a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis? , 2006, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[16]  T. Ishiguchi,et al.  Human comparative study of zinc and copper excretion via urine after administration of magnetic resonance imaging contrast agents. , 2005, Radiation medicine.

[17]  Dawn G Goodman,et al.  Best Practices Guideline: Toxicologic Histopathology , 2004, Toxicologic pathology.

[18]  M. Periasamy,et al.  Toxicological Assessment of Gadoversetamide Injection (OptiMARK®), a New Contrast-Enhancement Agent for Use in Magnetic Resonance Imaging , 2001, Investigative radiology.

[19]  J. Fregoneze,et al.  Central administration of zinc increases renal sodium and potassium excretion in rats , 1999, Brain Research.

[20]  R. Lauffer,et al.  Gadolinium(III) Chelates as MRI Contrast Agents: Structure, Dynamics, and Applications. , 1999, Chemical reviews.

[21]  H. Thomsen,et al.  Pharmacokinetics of gadodiamide injection in patients with severe renal insufficiency and patients undergoing hemodialysis or continuous ambulatory peritoneal dialysis. , 1998, Academic radiology.

[22]  W. Gibby,et al.  Human in vivo comparative study of zinc and copper transmetallation after administration of magnetic resonance imaging contrast agents. , 1996, Investigative radiology.

[23]  P. Wedeking,et al.  Biodistribution of Radiolabeled, Formulated Gadopentetate, Gadoteridol, Gadoterate, and Gadodiamide in Mice and Rats , 1995, Investigative radiology.

[24]  P. Gallé,et al.  Subcellular localization of gadolinium injected as soluble salt in rats: a microanalytical study. , 1995, Cellular and Molecular Biology.

[25]  P. Wedeking,et al.  Dose-dependent biodistribution of [153Gd]Gd(acetate)n in mice. , 1993, Nuclear medicine and biology.

[26]  E. Holtz,et al.  Preclinical safety assessment and pharmacokinetics of gadodiamide injection, a new magnetic resonance imaging contrast agent. , 1993, Investigative radiology.

[27]  G. Krestin,et al.  Pharmacokinetics of Gd-DTPA in patients with chronic renal failure. , 1991, Investigative radiology.

[28]  W. Haschek,et al.  Skin and Oral Mucosa , 2009 .

[29]  J. Zic,et al.  Gadolinium deposition in nephrogenic fibrosing dermopathy. , 2007, Journal of the American Academy of Dermatology.

[30]  S. Cowper,et al.  Gadolinium is detectable within the tissue of patients with nephrogenic systemic fibrosis. , 2007, Journal of the American Academy of Dermatology.

[31]  S. Cowper,et al.  Gadolinium is quantifiable within the tissue of patients with nephrogenic systemic fibrosis. , 2007, Journal of the American Academy of Dermatology.